Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Natco Pharma gains nearly 3% on ₹2,500 crore South Africa investment plan
Natco Pharma has announced investments of nearly ₹2,500 crore in South Africa, including infusing ₹1,400 crore in its arm in the country with an aim to enter new geographies.
Stocks in news: TCS, Nalco, Maruti Suzuki, Natco Pharma, HFCL
Indian markets saw a significant decline on Wednesday, influenced by global factors. TCS anticipates modest profit growth amid client spending caution and wage pressures. Nalco and NLC India will form a joint venture for a power plant. HFCL plans substantial investment to boost optical fibre cable production capacity. Natco Pharma announced significant investments and stake increases in South Africa.
Natco Pharma to invest Rs 2,500 crore in South Africa expansion
Natco Pharma will invest nearly Rs 2,500 crore in South Africa. This includes Rs 1,400 crore for its local subsidiary. The company will also increase its stake in Adcock Ingram. This acquisition is valued at Rs 1,069 crore. The transaction aims to expand Natco's geographic footprint.
39 NIFTY 500 stocks that delivered consistent growth over 5 years; Natco Pharma, ABB, M&M among top picks - Upstox
39 NIFTY 500 stocks that delivered consistent growth over 5 years; Natco Pharma, ABB, M&M among top picksUpstox
Lupin and alliance partner Natco receive USFDA approval for Eribulin Mesylate Injection
Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
Stock Picks Today: Dixon Tech, Natco Pharma, Ather Energy, NMDC And More On Brokerages' Radar
Brokerages' Radar
Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit
Buy Sell Hold
Natco Pharma stock price slips 20% in 2 days; should you buy, sell or hold?
Natco Pharma's management expects better FY28 with traction coming from Canada, Brazil and India besides some niche launches in the US which can translate into 15- 25 per cent PAT growth.
Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoY
Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins and lower annual earnings weighed on investor sentiment despite a one-time tax-related benefit recorded during the quarter and full financial year.
Natco Pharma Shares Fall 14% After Net Profit, Revenue Drops Over 39%
Shares of Natco Pharma dropped over 12% to Rs 1020.50 after the Q4FY26 results showed significant revenue and profit declines compared to the same quarter last year.
Natco Pharma tanks after Q4 profit declines 34% YoY to Rs 268 cr
Natco Pharma slipped 11.28% to Rs 1,043 after the company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore posted in the corresponding quarter last year.
Natco Pharma Ltd leads losers in 'A' group
Delta Corp Ltd, ISGEC Heavy Engineering Ltd, Jyoti CNC Automation Ltd and Bharat Dynamics Ltd are among the other losers in the BSE's 'A' group today, 29 May 2026.